Investing.com - Casi Pharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Casi Pharma announced earnings per share of $-0.3800 on revenue of $10.21M. Analysts polled by Investing.com EPS of $-0.4567 on revenue of $9.91M.
Casi Pharma 's are down 45% and is trading at $1.9600 , still down 81.75% from its 52 week high of $10.74 set on Monday, November 15, 2021.
Casi Pharma shares gained 0.51% to trade at $1.9600 in intra-day trade the report.
Casi Pharma follows other major Healthcare sector earnings this month
Casi Pharma's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar